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Summary
 
Interleukin-5 (IL-5) regulates the growth and function of eosinophils. It induces rapid tyrosine
phosphorylation of Lyn and Jak2 tyrosine kinases. The role of tyrosine phosphatases in IL-5
signal transduction has not been investigated. In this study, we provide first evidence that SH2
protein tyrosine phosphatase 2 (SHPTP2) phosphotyrosine phosphatase plays a key role in pre-
vention of eosinophil death by IL-5. We found that IL-5 produced a rapid activation and ty-
rosine phosphorylation of SHPTP2 within 1 min. The tyrosine phosphorylated SHPTP2 was
complexed with the adapter protein Grb2 in IL-5–stimulated eosinophils. Furthermore,
SHPTP2 appeared to physically associate with 
 
b
 
 common (
 
b
 
c
 
) chain of the IL-5 receptor (IL-
5
 
b
 
c
 
R). The association of SHPTP2 with IL-5
 
b
 
c
 
R was reconstituted using a synthetic phos-
photyrosine-containing peptide, 
 
b
 
c
 
 605–624, encompassing tyrosine (Y)
 
612
 
. The binding to the
phosphotyrosine-containing peptide increased the phosphatase activity of SHPTP2, whereas
the same peptide with the phosphorylated Y
 
612
 
®
 
F mutation did not activate SHPTP2. Only
SHPTP2 antisense oligonucleotides, but not sense SHPTP2, could inhibit tyrosine phosphory-
lation of microtubule-associated protein kinase, and reverse the eosinophil survival advantage
provided by IL-5. Therefore, we conclude that the physical association of SHPTP2 with the
phosphorylated 
 
b
 
c
 
 receptor and Grb2 and its early activation are required for the coupling of
the receptor to the Ras signaling pathway and for prevention of eosinophil death by IL-5.
 
E
 
osinophils play an integral role in the pathogenesis of
allergic and parasitic disorders (1). IL-5 is a cytokine
that primarily promotes the differentiation of eosinophils
from the stem cells and stimulates the survival and function
of mature eosinophils (2). This diverse effect of IL-5 on
eosinophils has been proposed as the key mechanism for
the development of blood and tissue eosinophilia in the
course of allergic inflammation.
IL-5R is a member of the hematopoietic receptor super-
family and is composed of a ligand-specific 
 
a
 
 subunit and
shared with IL-3 and GM-CSF 
 
b
 
 common (
 
b
 
c
 
) subunit
(3). Although neither of the receptor subunits contain a ki-
nase-like catalytic domain, IL-5 does induce a rapid and re-
versible tyrosine phosphorylation of various cellular pro-
teins (4). Recent findings indicate that for IL-5R type, the
binding of the ligand results in the activation of cytoplasmic
tyrosine kinases of the Jak/Tyk and Src type families (5, 6).
Indeed, we have shown that the stimulation of eosinophils
with IL-5 results in phosphorylation and activation of the
receptor-bound Lyn and Jak2 kinases. The consequence of
activation of these tyrosine kinases is the propagation of sig-
nal through the ras-raf-1-MEK-MAP (MAP, microtubule-
associated protein, MEK, MAP or Erk kinase) kinase path-
way and the Jak-STAT pathway. These observations clearly
support a major role of protein tyrosine phosphorylation in
IL-5–mediated signaling.
Little is known about the function of protein tyrosine
phosphatases (PTPs)
 
1
 
 in the signaling process initiated by the
receptors of the cytokine receptor superfamily. The PTP
Src homology (SH)PTP2, recently designated Src homol-
ogy 2 phosphatase 2 (SHP2) and also called PTP1D or Syp,
is one member of a small family of Src homology 2 (SH2)
domain–containing PTPs, which also includes Corkscrew
(Csw) and PTP-1C (also called SH-PTP1 or HCP) (7, 8).
SHPTP2 contains two SH2 domains and a single catalytic
domain. This phosphatase is ubiquitously expressed and
found to be tyrosine phosphorylated and activated in response
 
1
 
Abbreviations used in this paper: 
 
b
 
c
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b
 
 common;
 
 
 
ITIM, immunoreceptor
tyrosine-based inhibitory motif; MAP, microtubule-associated protein;
ODN, oligodeoxynucleotide; PDGF, platelet-derived growth factor;
PTP, protein tyrosine phosphatase; SH, Src homology.
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to erythropoietin, platelet-derived growth factor (PDGF),
prolactin, IL-3, and GM-CSF (9–12). Upon specific stimu-
lation, SHPTP2 binds to the receptor for PDGF and Epo.
Once phosphorylated on tyrosine, SHPTP2 generates a
binding site for the adapter protein, Grb2, which in turn
may lead to activation of the Ras-signaling pathway (13,
14). Although it has been postulated that PTPs function as
the negative regulators of the signal generated by protein
tyrosine kinases, several recent studies show that the inacti-
vation of SHPTP2 leads to a decrease in mitogenesis in re-
sponse to epidermal growth factor, PDGF, and insulin, in-
dicating that this phosphatase may, in some instances, act as
a positive signal transmitter (11, 15, 16).
The role of SHPTP2 in the IL-5 signal transduction in
eosinophils has not been investigated. In this study we in-
vestigated the phosphorylation state, association with other
proteins, and catalytic activity of this phosphatase after trig-
gering of the IL-5R. Furthermore, using specific antisense
oligodeoxynucleotides, we investigated the role of SHPTP2
in IL-5–mediated prolongation of eosinophil survival.
 
Materials and Methods
 
Reagents.
 
Percoll was purchased from Pharmacia, Inc. (Piscat-
away, NJ). The mAb against antiphosphotyrosine (clone 4G10) was
obtained from Upstate Biotechnology Inc. (Lake Placid, NY). Rab-
bit polyclonal anti-SHPTP2, anti-Grb2, anti-Erk 2, and mono-
clonal anti–IL-5
 
b
 
R antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Enhanced chemiluminescence
detection system was purchased from Amersham Corp. (Arling-
ton Heights, IL).
 
Eosinophil Purification.
 
Peripheral blood for eosinophil purifi-
cation was obtained from subjects with mild to moderate eosino-
philia (6–12%). Eosinophils were isolated by sedimentation with
3% hydroxyethyl starch, followed by centrifugation on discontin-
uous Percoll gradients according to the method of Gartner, as de-
scribed previously (17). The cells were further purified by nega-
tive selection using anti-CD16 immunomagnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany). Eosinophils (
 
.
 
99% pu-
rity) were then suspended in RPMI 1640 in tubes coated with
3% human serum albumin.
 
Preparation of Cytosolic Cell Extracts and Immunoprecipitation.
 
Eosinophils (2–4 
 
3
 
 10
 
6
 
/ml) were incubated with IL-5 at a con-
centration of 10
 
2
 
10
 
 M or medium at 37
 
8
 
C for 5 min. When ki-
netic studies were performed, IL-5 was added to samples at 0, 25,
and 29 min, and all samples were harvested at 30 min, i.e., eosin-
ophils were stimulated for 30, 5, and 1 min, respectively. This way
of stimulation allowed us to use one control sample, and all sam-
ples could be prepared simultaneously, under the same condi-
tions. The stimulation was terminated by addition of 1 vol of ice-
cold PBS containing 1 mM Na
 
3
 
VO
 
4
 
. The cells were pelleted by
centrifugation, washed rapidly with PBS, and lysed in a buffer con-
taining 50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA,
0.25% sodium deoxycholate, 1 mM PMSF, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM
NaF, 0.5% Triton X-100, and 1 
 
m
 
g/ml of aprotinin, leupeptin,
and pepstatin. For study of phosphatase activity, Na
 
3
 
VO
 
4
 
 was ex-
cluded from PBS and lysis buffer. After an incubation on ice for
10 min, the lysates were passaged several times through a 26-
gauge needle, and detergent insoluble materials were removed by
centrifugation at 4
 
8
 
C at 12,000 
 
g.
 
 The protein concentration was
determined using bicinchoninic acid assay (Pierce Chem. Co.,
Rockford, IL).
The cell lysates were precleared by incubation with 20 
 
m
 
l of
the protein A/G agarose Plus (Santa Cruz Biotechnology) for 2 h.
After removal of the beads, the lysates were incubated with ap-
propriate Ab (1–5 
 
m
 
g for each sample) and 25 
 
m
 
l of protein A/G
Agarose Plus for 4 to 6 h at 4
 
8
 
C. The immunoprecipitates were
washed three times with the cold lysis buffer and for SDS electro-
phoresis, boiled in twofold concentrated Laemmli reducing buffer
for 4 min.
 
Immune Complex Phosphatase Assay.
 
Immunoprecipitates of
SHPTP2 were prepared as described above and washed sequen-
tially 3 times with the cold lysis buffer (without Na
 
3
 
VO
 
4
 
) and 3
times with the phosphatase buffer (50 mM Hepes, pH 7.4, 60 mM
NaCl, 60 mM KCl, 0.1 mM PMSF, 1 
 
m
 
M pepstatin, 5 
 
m
 
g/ml
aprotinin, 1 
 
m
 
g/ml leupeptin) (15, 18). Phosphatase activity was
assayed by resuspending the final pellet in a total volume of 80 
 
m
 
l
of reaction buffer (phosphatase buffer, pH 5.5, containing 1 mg/ml
bovine serum albumin, 5 mM EDTA, 10 mM dithiothreitol). The
reaction was initiated by the addition of para-nitrophenyl phos-
phate (10 nM, final concentration) for 30 min at 30
 
8
 
C. The reac-
tion was stopped by the addition of 0.9 ml of 1 N NaOH, and
the absorbance of the samples was measured at 410 nm.
 
Peptide Binding Assay.
 
A biotinylated and tyrosine phosphor-
ylated peptide corresponding to the amino acid residues 605–624
of IL-5
 
b
 
R (biotin-PPPGSLE phosphorylated tyrosine (pY)
 
612
 
LCL-
PAGGQVQLV-NH
 
2
 
) was synthesized by the Quality Controlled
Biochemicals, Inc. (Hopkinton, MA). Two control peptides were
also synthesized. One control peptide had the same sequence ex-
cept pY
 
612
 
 was replaced with F. SHPTP2 is likely to bind 
 
b
 
c
 
through its SH2 domain. Since SH2 domain binds to pY only but
not to Y residues, we used a second control peptide derived from
 
b
 
c
 
 450–465 which contained two nonphosphorylated Y residues:
biotin-YGYRLRRKWEEKIPNP. All peptides had a COOH-
terminal amide. The peptides were purified by HPLC to 
 
.
 
95%
purity and evaluated by mass spectrometry for correct molecular
weight. The lyophilized peptides were reconstituted in distilled
water and then diluted in 100 mM Hepes, pH 7.4. For peptide
binding assay we used lysates from promyelocytic human cell line
HL-60, which expresses SHPTP2 (CCL 240; American Type
Culture Collection, Rockville, MD). These nondifferentiated
leukemic cells were maintained in RPMI 1640 with 10% FCS.
SHPTP2 immunoprecipitated from HL-60 has no detectable
phosphotyrosine and its basal phosphatase activity is comparable
to that obtained from nonstimulated eosinophils. HL-60 cell ly-
sates were prepared as described above and precleared with avi-
din-conjugated agarose beads (Sigma Chemical Co., St. Louis,
MO) for 1 h. Aliquots of cell lysates (equivalent to 10
 
7
 
 cells) were
then incubated with biotinylated peptides (50 
 
m
 
M) for 2–4 h, and
subsequently with avidin-conjugated agarose beads (50 
 
m
 
l) for 2 h
at 4
 
8
 
C. After the last incubation, the beads were washed five
times with the lysis buffer. The beads were suspended in 50 
 
m
 
l of
2 times concentrated electrophoresis buffer, boiled for 4 min, and
subjected to electrophoresis and Western blotting with anti-
SHPTP2 Ab.
In another set of experiments, HL-60 cell lysates (equivalent of
2 
 
3
 
 10
 
7
 
 cells) were incubated with appropriate peptides (100
 
m
 
M) for 2 h at 4
 
8
 
C, and then immunoprecipitated with anti-
SHPTP2 and subjected for phosphatase activity assay as described
above.
 
Gel Electrophoresis and Immunoblotting.
 
SDS–polyacrylamide gels
were prepared according to the Laemmli protocol and used for
immunoblotting. The concentration of polyacrylamide was either 
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7 or 12%, depending on the molecular weight range of the pro-
teins studied. Gels were blotted onto Hybond membranes for
Western blotting using the enhanced chemiluminescence system
(Amersham Corp.). Blots were incubated in blocking buffer con-
taining 5% BSA in TBST buffer (20 mM Tris base, 137 mM
NaCl, made to pH 7.6, and 0.05% Tween 20) for 1 h followed
by incubation with the primary Ab (0.1 
 
m
 
g/ml) for 1 h. After
washing five times in TBST buffer, blots were incubated for 30
min with a horseradish peroxidase conjugated secondary antibody
(0.1 
 
m
 
g/ml) directed against the primary Ab. The blots were de-
veloped with the enhanced chemiluminescence substrate accord-
ing to manufacturer’s protocol. In some experiments, blots were
reprobed with another Ab after stripping in a buffer of 62.5 mM
Tris-HCl (pH 6.7), 100 mM 2-mercaptoheptanol, and 2% SDS at
50
 
8
 
C for 30 min.
 
Antisense Oligodeoxynucleotides.
 
Three 20-mer oligodeoxynu-
cleotides (ODNs) were synthesized by Operon Technologies (Ala-
meda, CA) based on sequence information provided by H.E. Brox-
meyer (Indiana University Medical Center, Indianapolis, IN).
Sequences used were as follows: an antisense (CTCCGCGAT-
GTCATGTTCCT) of SHPTP2 199–219 nucleotides, a sense
(GAGGAACATGACATCGCGGA) for the same region, and a
nonsense (TGGGTGTGTCCAAGAGAACT). The ODNs were
phosphorothioate modified and resuspended in a sterile H
 
2
 
O at
100 
 
m
 
M concentration.
 
Eosinophil Survival Assay.
 
Purified eosinophils were suspended
at 10
 
6
 
/ml in RPMI 1640 without FCS and cultured in duplicate
in the presence of ODNs at concentration of 7.5 
 
m
 
M. After 6 h,
eosinophils were counted and cultured with IL-5 (10
 
2
 
10
 
 M) for
2 h. At this time, duplicates were lysed and subjected to immuno-
blotting for SHPTP2 expression. After treatment with IL-5, cells
were washed and resuspended in RPMI 1640 without IL-5, FCS,
and ODNs and cultured for another 24 h. The viability of the cul-
tured eosinophils was assessed immediately before and 24 h after
IL-5 stimulation. The relative amounts of dead cells were deter-
mined by uptake of 5 
 
m
 
M propidium iodide which was analyzed
under a fluorescence microscope. In some experiments, cells
were lysed after stimulation with IL-5 for 10 min and subjected
to immunoprecipitation with an anti–Erk-2 antibody followed by
Western blotting with antiphosphotyrosine antibody.
 
Results
 
Activation of SHPTP2.
 
It has been reported that the ty-
rosine phosphorylation of SHPTP2 is associated with its in-
creased phosphatase activity (19). Therefore, we first tested
whether IL-5 induced tyrosine phosphorylation of SHPTP2.
In this analysis, eosinophils were stimulated with IL-5 for
various time periods and then lysed and immunoprecipi-
tated with a polyclonal anti-SHPTP2 antibody. Western
blotting with an antiphosphotyrosine antibody revealed phos-
phorylation of SHPTP2 as early as 1 min, reaching the high-
est level 5 min after the stimulation (Fig. 1). This suggests a
relatively early involvement of SHPTP2 in the IL-5 signal-
ing pathway. Reprobing the membrane with the anti-
SHPTP2 antibody confirmed the presence of equal amounts
of the immunoprecipitated protein.
Next, we assessed whether IL-5 stimulated the enzy-
matic activity of SHPTP2. SHPTP2 was immunoprecipi-
tated from control or IL-5–treated eosinophils, and the
phosphatase activity was measured. The results are shown
in Fig. 2. The kinetics of phosphatase bioactivity was simi-
lar to the pattern of tyrosine phosphorylation, reaching the
peak in 5 min. A significant activity was detectable as late as
30 min after stimulation. A two- to threefold increase in
phosphatase activity was consistently observed in three in-
dependent experiments.
 
Physical Association with Grb2.
 
Once phosphorylated on
tyrosine, SHPTP2 conforms to the consensus binding site,
pYXNX, for the SH2 domain of Grb2 adapter protein
(20). Since the binding of Grb2 to SHPTP2 might explain
Ras activation after IL-5 stimulation, we asked whether
SHPTP2 could bind Grb2 in stimulated eosinophils. To
analyze the interaction between SHPTP2 and Grb2, first
we performed immunoprecipitation of Grb2 from IL-5–
stimulated and control cells followed by immunoblotting
with antiphosphotyrosine and anti-SHPTP2 antibodies.
As shown in Fig. 3 
 
A
 
, we detected a band of a 70-kD ty-
rosine phosphorylated protein in the immunoprecipitate of
Grb2 from IL-5–stimulated cells. Reprobing the same
membrane with the anti-SHPTP2 antibody confirmed the
presence of SHPTP2 in immunoprecipitate of Grb2 (Fig. 3
Figure 1. IL-5 induces tyrosine phosphorylation of SHPTP2 in eosino-
phils. Eosinophils were incubated with IL-5 as indicated for 1, 5, and 30
min. Cells were then lysed, and the cell lysates were immunoprecipitated
(IP) with anti-SHPTP2 antibody. The membranes were Western blotted
(WB) with antiphosphotyrosine (left) and anti-SHPTP2 (right) antibodies.
The left panel shows tyrosine-phosphorylated SHPTP2 bands in stimu-
lated eosinophils. The right panel confirms the position and amount of
SHPTP2. The bottom thick bands are due to the rabbit IgH in the im-
munoprecipitation.
Figure 2. SHPTP2 activity in
eosinophils stimulated with IL-5.
Eosinophils were stimulated with
IL-5 for 0, 1, 5, and 30 min at
378C. Cell lysates were im-
munoprecipitated with anti-
SHPTP2 antibody, and immu-
noprecipitates were assayed for
phosphatase activity using para-
nitrophenyl phosphate as a sub-
strate. Results are the means 6
SD of three experiments. *Sig-
nificantly different from the con-
trol at P ,0.05 (Student’s t test). 
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A
 
). In a next set of experiments, we looked for the pres-
ence of Grb2 in the immunoprecipitates of SHPTP2. As
shown in Fig. 3 
 
B
 
, Grb2 was detectable in the anti-
SHPTP2 immunoprecipitates and predictably, in the anti-
Grb2 immunoprecipitate from IL-5–stimulated eosinophils.
These experiments suggest a physical association of SHPTP2
and Grb2 that occurs in an IL-5–dependent manner.
 
Physical Association with IL-5
 
b
 
c
 
R.
 
The next set of coim-
munoprecipitation experiments was carried out to investi-
gate the physical association of SHPTP2 with IL-5
 
b
 
c
 
R. For
this purpose, eosinophil lysates were immunoprecipitated
with anti-SHPTP2 antibody and immunoblotted with anti-
receptor IL-5
 
b
 
c
 
 antibody. We found the presence of IL-5
 
b
 
c
 
R
in immunoprecipitate of SHPTP2 obtained from IL-5–stimu-
lated cells (Fig. 4 
 
A
 
). In the next set of experiments we
looked for the presence of SHPTP2 in immunoprecipitates
of IL-5
 
b
 
c
 
R. Western blotting with anti-SHPTP2 antibody
revealed the presence of the phosphatase in immunoprecip-
itate of IL-5
 
b
 
c
 
R (Fig. 4 
 
B
 
). The association between SHPTP2
and receptor appears to be present only in stimulated eosin-
ophils.
The binding of SHPTP2 with IL-5
 
b
 
c
 
R only in stimu-
lated cells suggests that the physical association occurs through
the SH2 domains of SHPTP2. The SH2 domain of SHPTP2
is predicted to bind to a consensus sequence of SXX-
pYXXL (21, 22). The 
 
bc subunit of IL-5R has seven ty-
rosine residues in cytosolic region and one of the tyrosine
residues at position 612 conforms best to the tyrosine bind-
ing motif of protein tyrosine phosphatases. We synthesized
a tyrosine phosphorylated (pY612) peptide encompassing
the residues 605–624 of IL-5bcR. Two peptides served as
controls. The first control peptide had the same sequence
except the replacement of pY612 with F. Since SH2 domain
binds to phosphorylated Y and not to nonphosphorylated
Y residues, we used a second control peptide, bc450–465
that contained two nonphosphorylated Y residues. All pep-
tides were biotinylated. For peptide binding experiments,
we used lysates from HL-60 cells instead of eosinophils.
HL-60 cells constitutively express SHPTP2 and served as a
readily available source of the phosphatase. The peptides
were incubated with HL-60 cell lysates and the precipitated
proteins were blotted with anti-SHPTP2 antibody. As
shown in Fig. 5, only the phosphotyrosine-containing pep-
tide bound SHPTP2. This experiment shows that the
phosphorylated b receptor can directly bind to SHPTP2
phosphatase.
To examine the potential effect of the IL-5bcR binding
to SHPTP2, we asked whether addition of the phospho-
peptide, bc 605–624 affected SHPTP2 activity. SHPTP2
activity was assayed in the absence or presence of the phos-
phopeptide. The mutated peptide was used as the control.
The addition of the phosphopeptide bc 605–624 strongly
Figure 3. Coimmunoprecipitation of SHPTP2 and Grb2 in IL-5–stim-
ulated eosinophils. (A) Cell lysates from IL-5–stimulated and unstimulated
eosinophils were immunoprecipitated (IP) with anti-Grb2 antibody. IL-5
(2) and (1) indicate cells incubated with medium or IL-5 for 5 min, re-
spectively. Immunoblotting with antiphosphotyrosine antibody revealed a
70-kD protein, suggesting the presence of SHPTP2 in the immunopre-
cipitate of Grb2 (left). Western blotting with anti-SHPTP2 antibody con-
firmed the identity of the phosphatase. (B) Eosinophils lysates were im-
munoprecipitated with anti-Grb2 antibody and anti-SHPTP2 antibody.
Western blotting with anti-Grb2 antibody revealed the presence of Grb2
in its own immunoprecipitates as well as in immunoprecipitates of
SHPTP2 from IL-5–stimulated eosinophils.
Figure 4. Coimmunoprecipitation of SHPTP2 and IL-5bcR in IL-5–
stimulated eosinophils. (A) Eosinophil lysates were immunoprecipitated
with a polyclonal anti-SHPTP2 antibody and subjected to Western blot
analysis with anti-SHPTP2 (left) and anti–IL-5bcR (right) antibodies. The
band of IL-5bcR was present in the immunoprecipitate of SHPTP2 ob-
tained from IL-5–stimulated cells. (B) Anti–IL-5bcR was used to immu-
noprecipitate lysates from eosinophils treated with (1) and without (2)
IL-5 (5 min). The resulting immunoblot was screened with anti–IL-5bcR
antibody showing the presence of equal amounts of the receptor and with
anti-SHPTP2 antibody revealing the presence of phosphatase in immu-
noprecipitate of IL-5bcR from stimulated eosinophils. Different intensity
of IgH is due to different isotypes of Abs used for immunoprecipitation
reacting with Western blotting secondary Ab.
Figure 5. The binding of
SHPTP2 to pY612 peptide. We
synthesized a phosphotyrosine-
based ITIM motif-containing
peptide (peptide 1) derived from
IL-5bcR (residues 605–624).
The controls were a nonphos-
phorylated F612 peptide (peptide
2) and a bc 450–465 peptide
(peptide 3). The peptides were
biotinylated and used in a peptide
binding assay using the HL-60
cell lysate. The bound proteins
were precipitated with streptavidin-agarose, followed by immunoblotting
with anti-SHPTP2. The first lane, (L, cell lysate) shows the position of
the 70-kD SHPTP2. The identity of the upper band is unknown. The
buffer control is shown in the last lane (0).565 Pazdrak et al.
stimulated SHPTP2 activity by more than fivefold (Fig. 6)
suggesting that binding of the phosphatase alone is respon-
sible for its activation. The mutated bc 605–624 peptide
did not activate the phosphatase.
Survival of Eosinophils Treated with SHPTP2 Antisense
ODNs. Since eosinophils are terminally differentiated
cells with life spans of z4 d, the use of antisense oligodeox-
ynucleotides is the most practical method to specifically al-
ter expression of SHPTP2. Eosinophils were incubated
with ODNs without FCS to protect stability of ODNs. As
demonstrated in Fig. 7, eosinophils exposed to 7.5 mM
antisense ODN for 6 h expressed little or no detectable
SHPTP2, whereas sense or nonsense ODNs did not alter
SHPTP2 level. Antisense ODNs used in our assay did not
alter expression of a closely related phosphatase SHPTP1
(data not shown). The viability of eosinophils assessed at
this time (immediately before stimulation with IL-5) always
exceeded 90% and was not different from control samples,
indicating that at concentration of 7.5 mM the ODNs were
not toxic to the cells. After 2 h of stimulation, eosinophils
were resuspended in medium without IL-5, ODNs, and
FCS. We excluded FCS from this stage of experiment,
since in a previous study by Inhorn et al., serum appeared
to alleviate the requirement for the Ras pathway for GM-
CSF–dependent viability and proliferation in mutant cells
with b receptor lacking the 626–763 amino acid residues
(23). Viability of the cells cultured without serum was al-
ways higher than 55% as assessed 24 h after stimulation with
IL-5. In contrast to IL-5–stimulated cells, there was usually
,40% viable control (not treated with IL-5) eosinophils at
the same time. However, as shown in Fig. 8, SHPTP2 an-
tisense oligonucleotides blocked the ability of IL-5 to pre-
vent eosinophil death (35.0 6 6.8 versus 66.2 6 8.0 versus
60.2  6 5.4% for antisense, sense, and nonsense ODN–
treated cells, respectively, P ,0.05) indicating critical role
of SHPTP2 phosphatase in IL-5–induced survival of eosin-
ophils.
Next we addressed the question of requirements of
SHPTP2 phosphatase in IL-5–induced phosphorylation of
MAP/Erk2 kinase. As shown in Fig. 9, there was signifi-
cant reduction in MAP kinase tyrosine phosphorylation in
eosinophils that were treated with the antisense ODNs. Since
MAP kinase is considered a downstream molecule of the
Ras signaling pathway, these results suggest that SHPTP2
plays a positive role in IL-5–induced activation of the Ras-
MAP kinase pathway.
Discussion
Previously, we have demonstrated that IL-5 stimulates
the phosphorylation and activation of the receptor-bound
tyrosine kinases in eosinophils. In this report, we show that
the IL-5 stimulation results in the phosphorylation and acti-
vation of the protein tyrosine phosphatase, SHPTP2. Others
have reported the tyrosine phosphorylation of SHPTP2 in
IL-3 and GM-CSF–stimulated murine myeloid cell lines (12).
Our data extend these findings by showing that SHPTP2
binds to the bc chain of the IL-5R in human eosinophils.
In additional studies, we have demonstrated that the ty-
rosine phosphorylated bc 605–624 peptide encompassing
pY612 binds and activates SHPTP2. There was no binding
of SHPTP2 to the same peptide when phosphotyrosine
(pY612) was replaced with phenylalanine. This is the first
Figure 6. SHPTP2 activity is
stimulated by pY612 peptide. HL-
60 cell lysates were incubated
with the control F612 (peptide 1)
and phosphorylated pY612 peptide
(peptide 2), and then immuno-
precipitated with anti-SHPTP2
and subjected for phosphatase as-
say. Shown are the means 6 SD
of six independent determina-
tions from two separate experi-
ments.  *Significantly different
from the control (peptide 1) at P
,0.05 (Student’s t test).
Figure 7. Effect of SHPTP2 oligodeoxynucleotides on SHPTP2 and
Erk2 expression. Whole cell lysates were prepared from eosinophils
treated with 7.5 mM SHPTP2 antisense (AS), sense (SS), and nonsense
(NS) ODNs or medium (0) for 6 h. The lysates with 10 mg of protein/lane
were resolved by SDS-PAGE. Anti-SHPTP2 and anti–Erk-2 Abs were
used in Western blot analysis to assess expression of proteins. Pretreatment
with SHPTP2 antisense ODN, but not with SS or NS, significantly de-
creased expression of SHPTP2 in eosinophils. Lower p42 band shows equal
amounts of Erk2 kinases not affected by treatment with ODNs.
Figure 8. SHPTP2 antisense
oligonucleotides block the sur-
vival promoting effect of IL-5.
Eosinophils were cultured in the
presence of 7.5 mM SHPTP2 an-
tisense (AS), sense (SS), and
nonsense (NS) ODNs or me-
dium for 6 h. Cells were then fur-
ther  incubated with or without
IL-5 (10210 M) for 2 h, and then
washed and incubated without
ODNs and IL-5 for an additional
24 h. No inhibition of eosino-
phil death by IL-5 was observed in SHPTP2 AS-treated cells. In contrast,
SHPTP2 SS- and NS-treated cells demonstrated a significant prolonga-
tion of eosinophil survival by IL-5. None of the ODNs at 7.5 mM con-
centration was toxic to eosinophils. Shown are the means 6 SD of five
independent experiments. *Significantly different from the cells not
treated with IL-5 at P ,0.05 (Student’s t test).566 The Involvement of SHPTP2 in IL-5 Signaling in Eosinophils
evidence that SHPTP2 directly interacts with the native
fragment of bc chain of IL-5R. Finally, we demonstrate the
requirement of the SHPTP2 for IL-5–induced phosphory-
lation of MAP/Erk2 kinase and prolongation of eosinophil
survival.
Specific domains within the bc receptor may contain in-
formation necessary to initiate distinct events such as prolif-
eration or differentiation through propagation of distinct
signaling pathways. Previous studies using a series of trun-
cated mutants revealed that the cytoplasmic domain of bc
contained two functional regions required for signaling (24).
The membrane proximal region (amino acid residues 456–
517) was shown to be essential for proliferation, activation
of Jak2 and pim-1, and induction of c-myc. A second do-
main (amino acid residues 627–763) was found to be neces-
sary for activation of Shc, p21 Ras, Raf-1, and MAP kinase
as well as for induction of c-fos and c-jun. It is noteworthy
that site-directed mutagenesis of tyrosine 750 to phenylala-
nine revealed a viability defect of mutated cells comparable
to deletion of the entire 627–763 domain (23). In a recent
work, Itoh et al. attempted to find the functional region of
the bc responsible for activation of Ras and induction of
c-fos promoter (25). They found that GM-CSF–induced ty-
rosine phosphorylation of two signaling molecules, Shc and
SHPTP2, functioning in Ras activation. As tyrosine phos-
phorylation of Shc was abrogated by the single substitution
at Y577 of the full-length bc receptor, Y577 has an essential
role in Shc activation. In contrast to Shc, both b589 trun-
cated and b wild with Y577®F mutation, were capable of
inducing tyrosine phosphorylation of SHPTP2, indicating
that activation of the phosphatase is mediated by multiple
sites, including Y577 as well as by other functional sites lo-
cated COOH-terminal to amino acid 589.
In our study, we found that bc coprecipitates with
SHPTP2, suggesting that physical association of these mol-
ecules occurs in IL-5–stimulated eosinophils. The direct as-
sociation of SHPTP2 and bc seems reasonable since the
synthetic 20-mer peptide, bc605–624 containing a phos-
phorylated tyrosine (Y612), was able to bind SHPTP2. How-
ever, the exact binding site for SHPTP2 on bc receptor re-
mains to be clarified. There are four tyrosine residues (Y612,
Y750, Y806, and Y869) located COOH-terminal to amino acid
589 on bc receptor surrounded by amino acid residues par-
tially matching a consensus sequence of Y(I/V)Xaa(V/I/L/P)
that favors the binding of the NH2-terminal SH2 domain
of SHPTP2 (21). We speculate that Y612 and/or Y750 are
likely binding sites for SHPTP2, since the sequence sur-
rounding Y612 and Y750 human IL-5bcR conform to the
so-called immunoreceptor tyrosine-based inhibitory motif
(ITIM) sequence motif of (T/S)XX(pY)XXL (22). Syn-
thetic phosphopeptides representing the ITIM sequence have
been shown to bind tyrosine phosphatases SHPTP1 and
SHPTP2 and, what is of much interest, this binding results
in dramatic increase in their phosphatase activity (26). In-
deed, we have shown that addition of a phosphotyrosine
peptide comprising the region around pY612 stimulates
SHPTP2 activity four- to sixfold, whereas the nonphos-
phorylated peptide has no stimulatory effect. The phos-
phorylated  bc 612–624 reported here is the first native pep-
tide derived from bc that potently stimulates SHPTP2
phosphatase activity.
The current model of the IL-5/IL-3/GM-CSF signaling
pathway predicts that the stimulation of the receptor by the
ligand causes the activation of the receptor bound tyrosine
kinases. The activated tyrosine kinases then tyrosine phos-
phorylate bc receptor. Tyrosine kinases bound to box 1
(W458–P465) are likely to be responsible for this event, since
deletion of this motif results in loss of tyrosine phosphory-
lation of bc (25). Indeed, in mutant cells lacking Jak2 ki-
nase, there was no phosphorylation of bc in response to
GM-CSF. Moreover, these cells failed to phosphorylate
SHPTP2 (27). We believe that one of the phosphorylated
tyrosines on bc creates the binding site for the SH2 domain
of SHPTP2. It is possible that SHPTP2 binds to more than
one phosphorylated tyrosine residue, and which one is crit-
ical for SHPTP2 activation remains to be determined. The
occupancy of SH2 domains results in an increase in phos-
phatase activity, presumably due to the induction of con-
formational changes in SHPTP2 (28). The role of increased
phosphatase activity of SHPTP2, as well as its target mole-
cule remains unclear. One possible target for activated
SHPTP2 phosphatase is bc. Upon bc binding, activated
SHPTP2 might attenuate the bc signal by dephosphorylat-
ing the receptor, receptor-associated proteins, or itself. How-
ever, the observation that SHPTP2 remains associated with
the phosphorylated IL-5bcR might argue against this model.
We did not observe dephosphorylation of bc, SHPTP2,
Jak2, and Lyn immunoprecipitated from IL-5–stimulated
cells at the time of maximal activation of SHPTP2 (data
not shown). An alternative possibility is that SHPTP2 acts
as a positive signal transducer by dephosphorylating inhibi-
Figure 9. SHPTP2 antisense oligodeoxynucleotides inhibit IL-5–
induced tyrosine phosphorylation of MAP/Erk2 kinase. Eosinophils were
cultured in the presence of 7.5 mM SHPTP2 antisense (AS) or sense (SS)
ODNs for 6 h, and then stimulated with IL-5 for 10 min. The cell lysates
were immunoprecipitated with anti-Erk2 Ab, resolved by SDS-PAGE,
and immunoblotted by an antiphosphotyrosine mAb (left) followed by
reprobing with anti-Erk-2 Ab (right). An increase in tyrosine phosphory-
lation of Erk2 was observed in eosinophils pretreated with sense ODN,
whereas pretreatment with antisense SHPTP2 significantly inhibited
IL-5–induced phosphorylation of MAP/Erk2 kinase. The blot is repre-
sentative of three independent experiments.567 Pazdrak et al.
tory phosphotyrosine residues. Although we did not ob-
serve inhibition of Lyn and Jak2 phosphorylation in eosin-
ophils lacking SHPTP2 phosphatase, we cannot exclude
other tyrosine kinases as a target of the phosphatase. Feng
et al. showed that SHPTP2 becomes constitutively tyrosine
phosphorylated in v-Src–transformed cells (29). The authors
suggested that SHPTP2 might dephosphorylate c-src on
Tyr527, whose phosphorylation blocks tyrosine kinase activ-
ity. IL-5 has been shown to activate several tyrosine kinases
including members of Src kinases family Lyn and Fyn and
tyrosine kinase Syk (5, 30, 31). Moreover, SHPTP2 and bc
have been shown to coprecipitate with PI-3 kinase (12).
Whether SHPTP2 is involved in regulation of any of these
kinases in response to IL-5 remains to be determined.
SHPTP2 is phosphorylated on tyrosine residues after IL-5
stimulation. However, the biological significance of this
event as well as its relation to phosphatase activity is not yet
clear. Our data predict that the binding to the receptor
alone stimulates its catalytic activity. This result is consis-
tent with a model in which IL-5 activates tyrosine kinases
and tyrosine kinases phosphorylate several tyrosines within
bc. SHPTP2 then binds, via its SH2, to one or two phos-
phorylated tyrosines, which leads to a conformational change
in SHPTP2 and an increase of phosphatase activity. Once
bound to the receptor, SHPTP2 becomes a target for re-
ceptor-associated tyrosine kinases, perhaps Jak2 or Lyn ki-
nases. It has been postulated that tyrosine phosphorylation
of SHPTP2 modulates its interaction with other SH2-con-
taining signaling proteins such as Grb2. Grb2 tends to bind to
YXNX motif which is present on SHPTP2 (e.g., Y542 and
Y580). The binding of SHPTP2 to Grb2 is inhibited by
phosphopeptide containing this motif (32). In our study,
SHPTP2 and Grb2 were coimmunoprecipitated by anti-
SHPTP2 and anti-Grb2 antibody, respectively. At this time
we do not know whether Grb2 also binds to bc receptor.
Grb2 is known to bind to nucleotide-exchange protein
Sos, which activates Ras. Thus, tyrosine phosphorylation of
SHPTP2 may result in recruitment of the Grb2–Sos com-
plex to the membrane, where the substrate for Sos, Ras, is
located (13).
Recently, it has been demonstrated that SHPTP2 func-
tions as a positive growth regulator. Microinjection of
anti-SHPTP2 antibody results in decreased insulin-medi-
ated mitogenesis (16). Mutant inactive forms of SHPTP2
strongly inhibited the mitogenic signals induced by PDGF,
a-thrombin (15), and IFN-a and -b (33). Further, negative
mutations of SHPTP2 led to inhibition of prolactin-induced
lactogenic signaling (11). Using antisense oligodeoxynucle-
otides against SHPTP2, we demonstrated a positive role of
the phosphatase in IL-5–induced activation of eosinophils.
Regardless of the target molecule for SHPTP2, this phos-
phatase appears to act upstream of Ras-Raf-MAP kinase
pathway activated in response to IL-5. Further, an activa-
tion of SHPTP2 phosphatase and Ras-Raf-MAP pathway
seems to be required for the delay of the death in eosino-
phils. In a recent paper, Yousefi et al. showed the require-
ment of Lyn and Syk tyrosine kinases for the prevention of
apoptosis by IL-5 and GM-CSF in eosinophils (31). Our
identification of SHPTP2 provides a further definition of
intracellular signaling pathways activated by IL-5 by show-
ing the requirement of the tyrosine phosphatase for eosino-
phil survival.
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